Pricing Log in Create free account

Enliven Therapeutics, Inc. (ELVN) vs Arcus Biosciences, Inc. (RCUS)

Enliven Therapeutics, Inc. and Arcus Biosciences, Inc. are both Biotechnology companies. Enliven Therapeutics, Inc. and Arcus Biosciences, Inc. are of similar size ($2.9B and $2.9B). Enliven Therapeutics, Inc. has the higher net margin (0.00% vs −393.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Enliven Therapeutics, Inc. leads on 11 and Arcus Biosciences, Inc. on 2.

Valuation

Metric ELVN RCUS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 23.84 9.71
P/B 2.76 6.01 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales n/m 18.70 9.21
Earnings yield (4.47%) (17.63%) (33.15%)
Free cash flow yield (2.71%) (17.07%) (25.50%)

Profitability

Metric ELVN RCUS Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (415.38%) 0.00%
Net margin 0.00% (393.16%) 0.00%
Free cash flow margin 0.00% (405.13%) 0.00%
Return on equity (15.31%) (90.82%) (56.36%)
Return on assets (14.98%) (46.02%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ELVN RCUS Biotechnology median
Revenue growth (TTM) — (55.34%) 6.02%
EPS growth (last fiscal year) 3.17% (4.78%) 30.26%
Revenue growth, 5-year CAGR — 25.93% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ELVN RCUS Biotechnology median
Debt to equity 0.00 0.22 0.00
Current ratio 64.07 3.82 4.72
Net debt to EBITDA 3.87 2.27 0.96

Dividend

Metric ELVN RCUS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ELVN RCUS Biotechnology median
Market cap 2.88b 2.91b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack